Phaseline

Companies › Dr. Willmar Schwabe GmbH & Co. KG

Dr. Willmar Schwabe GmbH & Co. KG: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Neurology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Extract of Ginkgo Biloba Leaves Tablets
Herbal extract with neuroprotective and cognitive enhancing properties
–Phase 4Ischemic Stroke HospitalizedDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07220538Extract of Ginkgo Biloba Leaves TabletsPhase 4Ischemic Stroke HospitalizedNeurologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Prilenia Ambros Therapeutics Cerevance Green Valley (Shanghai) Pharmaceuticals CereMark Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.